Literature DB >> 28438628

Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.

Francesco Cantiello1, Vincenzo Gangemi2, Giuseppe Lucio Cascini2, Ferdinando Calabria3, Marco Moschini4, Matteo Ferro5, Gennaro Musi5, Salvatore Butticè6, Andrea Salonia4, Alberto Briganti4, Rocco Damiano7.   

Abstract

OBJECTIVE: To assess the diagnostic accuracy of 64Copper prostate-specific membrane antigen (64Cu-PSMA) positron emission tomography/computed tomography (PET/CT) in the primary lymph node (LN) staging of a selected cohort of intermediate- to high-risk prostate cancer (PCa) patients.
MATERIALS AND METHODS: An observational prospective study was performed in 23 patients with intermediate- to high-risk PCa, who underwent 64Cu-PSMA PET/CT for local and lymph nodal staging before laparoscopic radical prostatectomy with an extended pelvic LN dissection. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for LN status of 64Cu-PSMA PET/CT were calculated using the final pathological findings as reference. Furthermore, we evaluated the correlation of intraprostatic tumor extent and grading with 64Cu-PSMA intraprostatic distribution.
RESULTS: Pathological analysis of LN involvement in 413 LNs harvested from our study cohort identified a total of 22 LN metastases in 8 (5%) of the 23 (35%) PCa patients. Imaging-based LN staging in a per-patient analysis showed that 64Cu-PSMA PET/CT was positive in 7 of 8 LN-positive patients (22%) with a sensitivity of 87.5%, specificity of 100%, PPV of 100%, and NPV of 93.7%, considering the maximum standardized uptake value (SUVmax) at 4 hours as our reference. Receiver operating characteristic curve was characterized by an area under the curve of 0.938. A significant positive association was observed between SUVmax at 4 hours with Gleason score, index, and cumulative tumor volume.
CONCLUSION: In our intermediate- to high-risk PCa patients study cohort, we showed the high diagnostic accuracy of 64Cu-PSMA PET/CT for primary LN staging before radical prostatectomy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28438628     DOI: 10.1016/j.urology.2017.04.019

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

Review 1.  [Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer].

Authors:  A Afshar-Oromieh; I Alberts; C Sachpekidis; A Rominger
Journal:  Urologe A       Date:  2019-12       Impact factor: 0.639

2.  64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer.

Authors:  Teli Liu; Chen Liu; Zhongyi Zhang; Ning Zhang; Xiaoyi Guo; Lei Xia; Jinquan Jiang; Qing Xie; Kun Yan; Steven P Rowe; Hua Zhu; Zhi Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-25       Impact factor: 9.236

Review 3.  Current status of theranostics in prostate cancer.

Authors:  Irene Virgolini; Clemens Decristoforo; Alexander Haug; Stefano Fanti; Christian Uprimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-28       Impact factor: 9.236

4.  The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.

Authors:  Nigel P Murray; Socrates Aedo; Cynthia Fuentealba; Eduardo Reyes; Anibal Salazar; Eghon Guzman; Shenda Orrego
Journal:  Ecancermedicalscience       Date:  2020-06-25

Review 5.  64Cu-based Radiopharmaceuticals in Molecular Imaging.

Authors:  Yeye Zhou; Jihui Li; Xin Xu; Man Zhao; Bin Zhang; Shengming Deng; Yiwei Wu
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

6.  Diagnostic Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy After Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Intermediate- and High-Risk Prostate Cancer Using the Magnetic Activity of Sentinel Nodes.

Authors:  Wiebke Geißen; Svenja Engels; Paula Aust; Jonas Schiffmann; Holger Gerullis; Friedhelm Wawroschek; Alexander Winter
Journal:  Front Pharmacol       Date:  2019-10-11       Impact factor: 5.810

7.  64Cu-DOTHA2-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window.

Authors:  Marie-Christine Milot; Ophélie Bélissant Benesty; Véronique Dumulon-Perreault; Samia Ait-Mohand; Patrick O Richard; Étienne Rousseau; Brigitte Guérin
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-13

8.  PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.

Authors:  Lars J Petersen; Helle D Zacho
Journal:  Cancer Imaging       Date:  2020-01-23       Impact factor: 3.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.